Tmem17b Antibody

What are the key differences between TMEM17 and TMEM176B proteins?

TMEM17 and TMEM176B represent distinct transmembrane proteins with different structures and functions:

TMEM17:

• 198 amino acids in length

• Encoded by a gene on human chromosome 2

• Primarily localized in the endoplasmic reticulum

• Functions in protein folding and trafficking

• Component of the tectonic-like complex at primary cilia transition zones

TMEM176B:

• Also known as LR8 or TORID (tolerance-related and induced)

• Functions as an immunoregulatory cation channel

• Member of the CD20-like MS4A family of proteins

• Highly expressed in monocytes, macrophages, and CD11b+ dendritic cells

• Plays critical roles in inflammasome regulation and antitumor immunity

How should I design validation experiments for TMEM17 antibodies in cancer research?

When validating TMEM17 antibodies for cancer research applications, implement a multi-step approach:

• Initial antibody validation: Perform Western blotting on cell lines with known TMEM17 expression patterns (e.g., MCF-7 and MDA-MB-231 breast cancer cell lines) to confirm specificity

• Knockdown/overexpression controls: Include TMEM17 siRNA knockdown controls alongside a scrambled siRNA to validate specificity. The expected molecular weight for TMEM17 is approximately 23 kDa

• Multiple detection methods: Validate with complementary techniques:

  • Western blotting (WB): Use 0.4 μg/ml concentration

  • Immunohistochemistry (IHC): Use 1:10-1:500 dilution

  • Immunofluorescence (IF): Use 1-4 μg/ml concentration

• Cross-reactivity testing: If working across species, verify antibody reactivity with mouse and rat samples in addition to human samples

What are optimal protocols for using TMEM176B antibodies in inflammasome activation studies?

For inflammasome activation studies using TMEM176B antibodies:

• Sample preparation:

  • For cell lysates: Extract total protein using lysis buffer and quantify via Bradford method

  • Load 50 μg of protein for SDS-PAGE separation

• Antibody incubation:

  • Primary incubation: Use anti-TMEM176B antibody at 1:200-1:1000 dilution (WB) overnight at 4°C

  • Secondary antibody: Appropriate species-specific HRP-conjugated antibody

• Functional assays to pair with TMEM176B detection:

  • Caspase-1 activity assay

  • IL-1β ELISA to measure inflammasome output

  • CD8+ T cell activation markers through flow cytometry

• Experimental controls:

  • Include TMEM176B knockout/knockdown cells alongside wildtype

  • Consider pharmacological inhibition with BayK8644 (TMEM176B inhibitor)

How can I effectively use TMEM176B antibodies to investigate immune checkpoint blockade enhancement?

To investigate TMEM176B's role in enhancing immune checkpoint blockade:

• In vitro experimental design:

  • Use complementary approaches: TMEM176B antibody detection, genetic knockdown, and pharmacological inhibition with BayK8644

  • Measure inflammasome activation markers: caspase-1 activity, IL-1β production

  • Assess CD8+ T cell-mediated cytotoxicity against tumor cells

• In vivo experimental approach:

  • Compare tumor growth in Tmem176b-/- and wild-type mice treated with anti-CTLA-4 or anti-PD-1 antibodies

  • Use anti-IL-1β neutralizing antibodies to verify inflammasome dependency

  • Analyze tumor-infiltrating lymphocytes (TILs) using TMEM176B antibodies in conjunction with CD8, NLRP3, and IL-1β markers

• Translational relevance:

  • Examine TMEM176B expression in patient samples before and after checkpoint blockade therapy

  • Correlate with inflammasome activation signature and clinical response

  • Consider combination of TMEM176B inhibition with checkpoint blockade in preclinical models

What are critical considerations when using TMEM17 antibodies for studying cancer progression mechanisms?

When investigating cancer progression using TMEM17 antibodies:

• Expression analysis workflow:

  • Compare TMEM17 expression between tumor and paired normal tissues using immunohistochemistry

  • Score staining intensity (0-3) and percentage of stained cells (1-4)

  • Calculate final score (0-12) with scores ≥4 considered positive expression

• Functional studies:

  • After TMEM17 knockdown, assess:

    • Cell proliferation via MTT assay

    • Colony formation capacity

    • Invasion using transwell assays

    • Migration via wound healing assay

• Signaling pathway investigation:

  • Use TMEM17 antibodies in conjunction with antibodies against p-AKT, p-GSK3β, active β-catenin, Snail, c-myc, cyclin D1, and E-cadherin

  • Include pathway inhibitors (e.g., LY294002 for AKT inhibition) to confirm mechanistic relationships

• Clinical correlation analysis:

  • Analyze TMEM17 expression in relation to T-stage, TNM stage, and lymph node metastasis

  • Consider survival analysis in relation to TMEM17 expression levels

How can I address inconsistent Western blot results when using TMEM176B antibodies?

To resolve inconsistent Western blot results with TMEM176B antibodies:

• Sample preparation optimization:

  • Ensure complete protein extraction using appropriate lysis buffers with protease inhibitors

  • Prepare fresh samples where possible, as TMEM176B may be sensitive to freeze-thaw cycles

  • Verify protein concentration using Bradford or BCA assays

• Detection optimization:

  • Expected molecular weight considerations: TMEM176B appears at 23-31 kDa (reported 23 kDa theoretical weight but observed at 31 kDa in some tissues)

  • Membrane transfer conditions: Use PVDF membranes for optimal protein retention

  • Blocking conditions: Test both 5% BSA and 5% non-fat dry milk to reduce background

• Antibody selection and validation:

  • Validate antibody specificity using TMEM176B overexpression or knockout controls

  • Consider using antibodies targeting different epitopes (N-terminal vs. C-terminal)

  • Verify cross-reactivity if working with non-human samples

• Signal enhancement techniques:

  • For low-abundance samples, consider using HRP-conjugated secondary antibodies with enhanced chemiluminescence

  • Optimize exposure times to prevent signal saturation

What methodological approaches should I use to study TMEM17's role in cellular localization?

To effectively study TMEM17's subcellular localization:

• Immunofluorescence protocol optimization:

  • Fixation method: 4% paraformaldehyde (10 minutes) followed by permeabilization with 0.5% Triton X-100

  • Blocking: Use 10% goat serum with 0.1% Triton X-100 and 10 mg/mL BSA for 1 hour

  • Primary antibody concentration: 1-4 μg/ml for TMEM17 antibody

• Co-localization studies:

  • Pair TMEM17 antibody with markers for:

    • Endoplasmic reticulum (e.g., calnexin, PDI)

    • Golgi apparatus (e.g., GM130)

    • Primary cilia (e.g., acetylated tubulin)

    • Cell membrane (e.g., Na+/K+ ATPase)

• Advanced imaging approaches:

  • Super-resolution microscopy (STED or STORM) for precise localization

  • Live-cell imaging using TMEM17-fluorescent protein fusions to complement antibody-based detection

  • Electron microscopy with immunogold labeling for ultrastructural localization

• Fractionation validation:

  • Complement imaging with biochemical subcellular fractionation

  • Verify TMEM17 distribution using the same antibody in Western blotting of different cellular fractions

How can TMEM176B antibodies be employed to develop therapeutic strategies for cancer immunotherapy?

Using TMEM176B antibodies to develop cancer immunotherapy approaches:

• Antibody screening strategies:

  • Develop and screen for TMEM176B-neutralizing antibodies

  • Test antibody effects on cell proliferation in cancer cell lines (e.g., breast cancer MDA-MB-231 cells)

  • Evaluate antibody-mediated modulation of inflammasome activation

• Combination therapy investigation:

  • Use TMEM176B antibodies to identify patients likely to respond to checkpoint blockade

  • Investigate synergy between TMEM176B inhibition and anti-CTLA-4 or anti-PD-1 therapies

  • Monitor inflammasome activation as a biomarker of response

• Antibody development approach:

  • Target the extracellular domains of TMEM176B

  • Use techniques similar to those described for generating polyclonal sera:

    • DNA immunization with full-length TMEM176B

    • Focus on the large extracellular loop #2 for antibody development

    • Screen sera for TMEM176B reactivity

• Translational considerations:

  • Patient stratification based on TMEM176B expression levels

  • Monitor immune infiltrates and inflammasome activation in treated tumors

  • Assess safety through monitoring for autoimmune-like side effects

What are the emerging applications of TMEM17 antibodies in studying epithelial-mesenchymal transition (EMT)?

For investigating TMEM17's role in EMT using specific antibodies:

• Expression correlation studies:

  • Compare TMEM17 expression with EMT markers (E-cadherin, Vimentin, Snail) across cancer types

  • Use multiplex immunofluorescence to co-localize TMEM17 with EMT markers in tissue samples

  • Quantify expression changes during EMT induction

• Signaling pathway analysis:

  • Use TMEM17 antibodies alongside key signaling molecules:

    • AKT and p-AKT (Ser 473)

    • GSK3β and p-GSK3β (Ser 9)

    • Active β-catenin

    • EMT-related transcription factors (Snail, Slug, ZEB1/2)

    • Investigate the potential role of FGFR/JNK signaling as observed with TMEM176B

• Functional validation experiments:

  • TMEM17 knockdown/overexpression followed by:

    • Invasion assays (transwell)

    • Migration assays (wound healing)

    • 3D culture morphology assessment

    • Expression analysis of EMT markers

• Metastasis model investigations:

  • Use TMEM17 antibodies to track expression in primary tumors vs. metastatic lesions

  • Consider TMEM17 inhibition as a potential strategy to reduce metastatic potential

What are the key criteria for selecting appropriate TMEM antibodies for specific research applications?

When selecting TMEM antibodies for research:

Consider:

• Target localization needs (membrane vs. intracellular)

• Sensitivity requirements for low-expression samples

• Cross-reactivity requirements for comparative studies

• Application-specific performance data

How should researchers validate newly purchased TMEM antibodies before experimental use?

Comprehensive validation protocol for new TMEM antibodies:

• Specificity testing:

  • Positive control: Tissues/cells with known high expression (e.g., A549 cells, human placenta tissue for TMEM176B)

  • Negative control: Knockout/knockdown samples or tissues with minimal expression

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide to confirm specificity

• Application-specific optimization:

  • Western blot: Titrate antibody (1:200-1:1000), optimize blocking conditions

  • IHC: Test multiple antigen retrieval methods and antibody dilutions (1:10-1:500)

  • IF: Optimize fixation method and antibody concentration (1-4 μg/ml)

• Cross-platform validation:

  • Compare antibody results across multiple detection methods

  • Verify that expression patterns match mRNA expression data from databases

• Lot-to-lot consistency check:

  • Run side-by-side comparisons of different antibody lots on identical samples

  • Document optimal conditions for each lot to maintain experimental consistency

How should researchers interpret contradictory findings when using different TMEM176B antibody clones?

When facing contradictory results with different TMEM176B antibody clones:

• Epitope mapping analysis:

  • Determine the specific epitopes recognized by each antibody clone

  • Consider potential post-translational modifications that might affect epitope accessibility

  • Evaluate potential protein isoforms that might be differentially detected

• Systematic comparison approach:

  • Test all antibody clones side-by-side on the same samples under identical conditions

  • Use multiple detection methods (WB, IHC, IF) to cross-validate findings

  • Include genetic manipulation controls (overexpression, knockdown) with each antibody

• Biological context consideration:

  • Evaluate cellular context differences that might affect TMEM176B expression or localization

  • Consider protein-protein interactions that might mask certain epitopes

  • Examine potential processing or cleavage events that could affect detection

• Independent validation methods:

  • Use mass spectrometry to confirm protein identity and abundance

  • Employ RNA-level analysis (qPCR, RNA-seq) to correlate with protein findings

  • Consider complementary approaches like proximity ligation assays to verify interactions

What bioinformatic approaches can complement TMEM17 antibody studies in cancer research?

Integrative bioinformatic approaches to enhance TMEM17 antibody studies:

• Expression database utilization:

  • Mining TCGA, METABRIC, and GEO datasets for TMEM17 expression patterns

  • Analysis platforms to consider:

    • cBioportal for Cancer Genomics

    • UALCAN cancer database

    • Gene Expression database of Normal and Tumor Tissues 2 (GENT2)

    • Kaplan-Meier plotter for survival correlation

• Single-cell RNA sequencing integration:

  • Analyze cell-type specific expression of TMEM17

  • Identify co-expression networks

  • Correlate with protein-level findings from antibody studies

• Pathway analysis approaches:

  • Gene Set Enrichment Analysis (GSEA) to identify pathways associated with TMEM17 expression

  • Protein-protein interaction network analysis using STRING or BioGRID

  • Correlation with AKT/GSK3β/β-catenin pathway components

• Clinical outcome correlation:

  • Stratify patient data based on TMEM17 expression levels

  • Correlate with clinicopathological parameters

  • Perform multivariate survival analysis to assess prognostic value